{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T22:26:24Z","timestamp":1787955984636,"version":"build-2784847793"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T00:00:00Z","timestamp":1771459200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":4,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100004047","name":"Karolinska Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100004047","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>An earlier study suggested that longer intervals between diagnosis and treatment of uveal melanoma are associated with worse prognosis. We evaluated whether a similar association could be observed in an independent cohort.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Retrospective cohort of 336 patients with posterior uveal melanoma treated at a single referral center (2000\u20132011), assembled by investigators independent of the original report. We compared disease-specific (DSS) and overall survival (OS) across prespecified diagnosis-to-treatment intervals (\u2264\u200915, 30, 45 days) using cumulative-incidence (Gray\u2019s) and Kaplan\u2013Meier analyses (unmatched and propensity-matched). Fine\u2013Gray regression with treatment day as time zero estimated the subdistribution hazard ratio per 10-day delay.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Tumor size and stage at diagnosis did not differ between patients treated within 30 days (prompt) and those treated after 30 days (delayed). In competing-risk analysis, delayed treatment was associated with a higher cumulative incidence of metastatic death. Kaplan\u2013Meier OS\u2014but not DSS\u2014differed significantly between prompt and delayed treatment. A model of exponential tumor growth indicated that deferring treatment of a lesion of a medium-sized tumor by one month is associated with an estimated absolute increase in the 10-year competing-risk incidence of metastatic death by \u2248\u20090.8%.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>While treatment delay is unlikely to be among the strongest prognostic factors in uveal melanoma, this independent validation cohort supports an association between diagnosis-to-treatment intervals beyond about one month and worse survival.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12885-026-15775-z","type":"journal-article","created":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T06:16:00Z","timestamp":1771481760000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Independent validation of time to treatment as a prognostic factor in uveal melanoma"],"prefix":"10.1186","volume":"26","author":[{"given":"Annahita","family":"Moghadam","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viktor Torgny","family":"Gill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiva","family":"Sabazade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Hagstr\u00f6m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustav","family":"St\u00e5lhammar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,19]]},"reference":[{"key":"15775_CR1","doi-asserted-by":"publisher","first-page":"101041","DOI":"10.1016\/j.preteyeres.2022.101041","volume":"90","author":"ES Rantala","year":"2022","unstructured":"Rantala ES, Hernberg MM, Piperno-Neumann S, Grossniklaus HE, Kivela TT. Metastatic uveal melanoma: The final frontier. Prog Retin Eye Res. 2022;90:101041.","journal-title":"Prog Retin Eye Res"},{"issue":"13","key":"15775_CR2","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1056\/NEJMoa2103485","volume":"385","author":"P Nathan","year":"2021","unstructured":"Nathan P, Hassel JC, Rutkowski P, Baurain JF, Butler MO, Schlaak M, Sullivan RJ, Ochsenreither S, Dummer R, Kirkwood JM, et al. Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma. N Engl J Med. 2021;385(13):1196\u2013206.","journal-title":"N Engl J Med"},{"issue":"2","key":"15775_CR3","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1111\/ceo.14496","volume":"53","author":"G Stalhammar","year":"2025","unstructured":"Stalhammar G. Uveal Melanoma Treatment: A Paradigm Shift? Clin Exp Ophthalmol. 2025;53(2):113\u20135.","journal-title":"Clin Exp Ophthalmol"},{"issue":"3","key":"15775_CR4","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1038\/sj.bjc.6605765","volume":"103","author":"B Damato","year":"2010","unstructured":"Damato B. Does ocular treatment of uveal melanoma influence survival? Br J Cancer. 2010;103(3):285.","journal-title":"Br J Cancer"},{"issue":"6","key":"15775_CR5","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1136\/bjo.62.6.420","volume":"62","author":"LE Zimmerman","year":"1978","unstructured":"Zimmerman LE, McLean IW, Foster WD. Does enucleation of the eye containing a malignant melanoma prevent or accelerate the dissemination of tumour cells. Br J Ophthalmol. 1978;62(6):420.","journal-title":"Br J Ophthalmol"},{"issue":"10","key":"15775_CR6","doi-asserted-by":"publisher","first-page":"1382","DOI":"10.1001\/archopht.1993.01090100090033","volume":"111","author":"JJ Augsburger","year":"1993","unstructured":"Augsburger JJ, Vrabec TR. Impact of delayed treatment in growing posterior uveal melanomas. Arch Ophthalmol. 1993;111(10):1382\u20136.","journal-title":"Arch Ophthalmol"},{"issue":"s244","key":"15775_CR7","first-page":"0","volume":"87","author":"B Damato","year":"2009","unstructured":"Damato B, Coupland S. Does delayed treatment shorten the life of patients with fatal choroidal melanoma? Acta Ophthalmol. 2009;87(s244):0\u20130.","journal-title":"Acta Ophthalmol"},{"issue":"9","key":"15775_CR8","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1016\/j.ophtha.2024.05.001","volume":"131","author":"RN Hussain","year":"2024","unstructured":"Hussain RN, Coupland SE, Heimann H, Eleuteri A. Re: Stalhammar G: Delays between uveal melanoma diagnosis and treatment increase the risk of metastatic death (Ophthalmology. 2024;131:1094\u20131104). Ophthalmology. 2024;131(9):e39.","journal-title":"Ophthalmology"},{"issue":"1","key":"15775_CR9","doi-asserted-by":"publisher","first-page":"8923","DOI":"10.1038\/s41598-021-88390-6","volume":"11","author":"OE Uner","year":"2021","unstructured":"Uner OE, See TRO, Szalai E, Grossniklaus HE, Stalhammar G. Estimation of the timing of BAP1 mutation in uveal melanoma progression. Sci Rep. 2021;11(1):8923.","journal-title":"Sci Rep"},{"issue":"7","key":"15775_CR10","doi-asserted-by":"publisher","first-page":"734","DOI":"10.1001\/jamaophthalmol.2016.0913","volume":"134","author":"SD Walter","year":"2016","unstructured":"Walter SD, Chao DL, Feuer W, Schiffman J, Char DH, Harbour JW. Prognostic Implications of Tumor Diameter in Association With Gene Expression Profile for Uveal Melanoma. JAMA Ophthalmol. 2016;134(7):734\u201340.","journal-title":"JAMA Ophthalmol"},{"issue":"4","key":"15775_CR11","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1016\/j.ophtha.2023.10.026","volume":"131","author":"G Stalhammar","year":"2023","unstructured":"Stalhammar G, Coupland SE, Ewens KG, Ganguly A, Heimann H, Shields CL, Damato B. Improved Staging of Ciliary Body and Choroidal Melanomas Based on Estimation of Tumor Volume and Competing Risk Analyses. Ophthalmology. 2023;131(4):478\u201391.","journal-title":"Ophthalmology"},{"issue":"8","key":"15775_CR12","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1016\/S0161-6420(00)00182-2","volume":"107","author":"S Eskelin","year":"2000","unstructured":"Eskelin S, Pyrh\u00f6nen S, Summanen P, Hahka-Kemppinen M, Kivel\u00e4 T. Tumor doubling times in metastatic malignant melanoma of the uvea: tumor progression before and after treatment. Ophthalmology. 2000;107(8):1443\u20139.","journal-title":"Ophthalmology"},{"issue":"5","key":"15775_CR13","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1016\/S0161-6420(00)00607-2","volume":"108","author":"AD Singh","year":"2001","unstructured":"Singh AD. Uveal melanoma: implications of tumor doubling time. Ophthalmology. 2001;108(5):829\u201330.","journal-title":"Ophthalmology"},{"issue":"22","key":"15775_CR14","doi-asserted-by":"publisher","first-page":"3834","DOI":"10.3390\/cancers16223834","volume":"16","author":"G Stalhammar","year":"2024","unstructured":"Stalhammar G, Grisanti S, Finger PT On the Prognostic Implication of Delays in the Definitive Treatment of Uveal Melanoma. Cancers (Basel). 2024;16(22):3834. https:\/\/doi.org\/10.3390\/cancers16223834.","journal-title":"Cancers (Basel)"},{"key":"15775_CR15","doi-asserted-by":"publisher","first-page":"103652","DOI":"10.1016\/j.critrevonc.2022.103652","volume":"172","author":"G Stalhammar","year":"2022","unstructured":"Stalhammar G, Gill VT. The long-term prognosis of patients with untreated primary uveal melanoma: A systematic review and meta-analysis. Crit Rev Oncol Hematol. 2022;172:103652.","journal-title":"Crit Rev Oncol Hematol"},{"issue":"9","key":"15775_CR16","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.ophtha.2023.11.021","volume":"131","author":"G Stalhammar","year":"2024","unstructured":"Stalhammar G. Delays between Uveal Melanoma Diagnosis and Treatment Increase the Risk of Metastatic Death. Ophthalmology. 2024;131(9):1094\u2013104.","journal-title":"Ophthalmology"},{"key":"15775_CR17","doi-asserted-by":"publisher","first-page":"m4087","DOI":"10.1136\/bmj.m4087","volume":"371","author":"TP Hanna","year":"2020","unstructured":"Hanna TP, King WD, Thibodeau S, Jalink M, Paulin GA, Harvey-Jones E, O\u2019Sullivan DE, Booth CM, Sullivan R, Aggarwal A. Mortality due to cancer treatment delay: systematic review and meta-analysis. BMJ. 2020;371:m4087.","journal-title":"BMJ"},{"issue":"8","key":"15775_CR18","doi-asserted-by":"publisher","first-page":"1607","DOI":"10.3390\/cancers16081607","volume":"16","author":"B Damato","year":"2024","unstructured":"Damato B, Eleuteri A, Taktak A, Hussain R, Fili M, Stalhammar G, Heimann H, Coupland SE Deferral of Treatment for Small Choroidal Melanoma and the Risk of Metastasis: An Investigation Using the Liverpool Uveal Melanoma Prognosticator Online (LUMPO). Cancers (Basel). 2024;16(8):1607. https:\/\/doi.org\/10.3390\/cancers16081607.","journal-title":"Cancers (Basel)"},{"issue":"1","key":"15775_CR19","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1016\/j.survophthal.2024.09.004","volume":"70","author":"G Stalhammar","year":"2025","unstructured":"Stalhammar G, Hagstrom A, Ermedahl Conradi M, Williams PA. Choroidal nevi and melanoma doubling times and implications for delays in treatment: A systematic review and meta-analysis. Surv Ophthalmol. 2025;70(1):38\u201346.","journal-title":"Surv Ophthalmol"},{"key":"15775_CR20","doi-asserted-by":"publisher","unstructured":"Stalhammar G. Brachytherapy with 15 versus 20\u00a0mm Ruthenium-106 Plaques Without Verification of Plaque Position is Associated with Local Tumor Recurrence and Death in Posterior Uveal Melanoma. Int J Radiat Oncol Biol Phys. 2023;117(5):1125\u201337. https:\/\/doi.org\/10.1016\/j.ijrobp.2023.06.077.","DOI":"10.1016\/j.ijrobp.2023.06.077"},{"issue":"4","key":"15775_CR21","doi-asserted-by":"publisher","first-page":"381","DOI":"10.1038\/sj.bmt.1705727","volume":"40","author":"L Scrucca","year":"2007","unstructured":"Scrucca L, Santucci A, Aversa F. Competing risk analysis using R: an easy guide for clinicians. Bone Marrow Transpl. 2007;40(4):381\u20137.","journal-title":"Bone Marrow Transpl"},{"issue":"7","key":"15775_CR22","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1001\/archopht.1997.01100160056009","volume":"115","author":"Collaborative Ocular Melanoma Study Group","year":"1997","unstructured":"Collaborative Ocular Melanoma Study Group. Mortality in patients with small choroidal melanoma. COMS report 4. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol. 1997;115(7):886\u201393.","journal-title":"Arch Ophthalmol"},{"issue":"7","key":"15775_CR23","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1001\/archopht.119.7.969","volume":"119","author":"M Diener-West","year":"2001","unstructured":"Diener-West M, Earle JD, Fine SL, Hawkins BS, Moy CS, Reynolds SM, Schachat AP, Straatsma BR, Group COMS. The COMS randomized trial of iodine 125 brachytherapy for choroidal melanoma, III: initial mortality findings. COMS Report 18. Arch Ophthalmol. 2001;119(7):969\u201382.","journal-title":"Arch Ophthalmol"},{"issue":"6","key":"15775_CR24","doi-asserted-by":"publisher","first-page":"936","DOI":"10.1016\/j.ajo.2004.07.006","volume":"138","author":"BS Hawkins","year":"2004","unstructured":"Hawkins BS, Group COMS. The Collaborative Ocular Melanoma Study (COMS) randomized trial of pre-enucleation radiation of large choroidal melanoma: IV. Ten-year mortality findings and prognostic factors. COMS report number 24. Am J Ophthalmol. 2004;138(6):936\u201351.","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"15775_CR25","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1038\/s41467-017-02428-w","volume":"9","author":"MG Field","year":"2018","unstructured":"Field MG, Durante MA, Anbunathan H, Cai LZ, Decatur CL, Bowcock AM, Kurtenbach S, Harbour JW. Punctuated evolution of canonical genomic aberrations in uveal melanoma. Nat Commun. 2018;9(1):116.","journal-title":"Nat Commun"},{"key":"15775_CR26","doi-asserted-by":"publisher","unstructured":"Stalhammar G, Kalirai H, Coupland SE, Grisanti S, Sonntag SR, Tura A, Eleuteri A, Hussain RN, Heimann H. Coude Adam H. Metastatic potential of small posterior uveal melanomas. Acta Ophthalmol. 2026;104(2):191\u2013203. https:\/\/doi.org\/10.1111\/aos.17582.","DOI":"10.1111\/aos.17582"},{"issue":"7","key":"15775_CR27","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1001\/archophthalmol.2011.181","volume":"129","author":"SA Callejo","year":"2011","unstructured":"Callejo SA, Dopierala J, Coupland SE, Damato B. Sudden growth of a choroidal melanoma and multiplex ligation-dependent probe amplification findings suggesting late transformation to monosomy 3 type. Arch Ophthalmol. 2011;129(7):958\u201360.","journal-title":"Arch Ophthalmol"},{"issue":"9","key":"15775_CR28","doi-asserted-by":"publisher","first-page":"967","DOI":"10.1136\/bjo-2025-327294","volume":"109","author":"G Stalhammar","year":"2025","unstructured":"Stalhammar G. Twelve reasons delays in uveal melanoma treatment might affect prognosis. Br J Ophthalmol. 2025;109(9):967\u20139.","journal-title":"Br J Ophthalmol"},{"key":"15775_CR29","doi-asserted-by":"publisher","unstructured":"Yavuzyigitoglu S, Sabazade S, Gill V, Brosens E, Kili\u00e7 E, St\u00e5lhammar G. Higher AJCC Stage at Primary Tumor Diagnosis May Predict Shorter Survival in Metastatic Uveal Melanoma. Sci Rep. 2025;15(1);19557. https:\/\/doi.org\/10.1038\/s41598-025-03961-1.","DOI":"10.1038\/s41598-025-03961-1"},{"issue":"1","key":"15775_CR30","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/S0002-9394(02)02270-5","volume":"136","author":"BR Straatsma","year":"2003","unstructured":"Straatsma BR, Diener-West M, Caldwell R, Engstrom RE. Collaborative Ocular Melanoma Study G: Mortality after deferral of treatment or no treatment for choroidal melanoma. Am J Ophthalmol. 2003;136(1):47\u201354.","journal-title":"Am J Ophthalmol"},{"key":"15775_CR31","doi-asserted-by":"publisher","unstructured":"Witzenhausen H, Stalhammar G. Survival Benefit of Primary Tumor Treatment in Uveal Melanoma: A Re-Analysis of the Collaborative Ocular Melanoma Study (COMS) and Natural History Study (NHS) Cohorts. Cancers (Basel). 2024;16(22):3839. https:\/\/doi.org\/10.3390\/cancers16223839.","DOI":"10.3390\/cancers16223839"},{"issue":"2","key":"15775_CR32","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1093\/ajcp\/aqad029","volume":"160","author":"VT Gill","year":"2023","unstructured":"Gill VT, Norrman E, Sabazade S, Karim A, Lardner E, Stalhammar G. Multiorgan Involvement of Dormant Uveal Melanoma Micrometastases in Postmortem Tissue From Patients Without Coexisting Macrometastases. Am J Clin Pathol. 2023;160(2):160\u201374.","journal-title":"Am J Clin Pathol"},{"issue":"12","key":"15775_CR33","doi-asserted-by":"publisher","first-page":"1290","DOI":"10.1016\/j.ophtha.2023.07.025","volume":"130","author":"S Grisanti","year":"2023","unstructured":"Grisanti S, Schindler F, Merz H, Kakkassery V, Sonntag SR, Tura A. Detection of Circulating Tumor Cells in Patients with Small Choroidal Melanocytic Lesions. Ophthalmology. 2023;130(12):1290\u2013303.","journal-title":"Ophthalmology"},{"issue":"7","key":"15775_CR34","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1038\/s41588-019-0440-9","volume":"51","author":"AH Shain","year":"2019","unstructured":"Shain AH, Bagger MM, Yu R, Chang D, Liu S, Vemula S, Weier JF, Wadt K, Heegaard S, Bastian BC, et al. The genetic evolution of metastatic uveal melanoma. Nat Genet. 2019;51(7):1123\u201330.","journal-title":"Nat Genet"},{"issue":"6","key":"15775_CR35","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1111\/aos.17492","volume":"103","author":"L Klaassen","year":"2025","unstructured":"Klaassen L, Ferreira TA, Luyten G, Beenakker JM. Estimating uveal melanoma volume with ellipsoid tumour models. Acta Ophthalmol. 2025;103(6):691\u20138.","journal-title":"Acta Ophthalmol"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-026-15775-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-026-15775-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T18:28:15Z","timestamp":1781634495000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12885-026-15775-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,19]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["15775"],"URL":"https:\/\/doi.org\/10.1186\/s12885-026-15775-z","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,19]]},"assertion":[{"value":"1 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was approved by the Swedish Ethical Review Authority (reference 2023-02952-02) and adhered to the tenets of the declaration of Helsinki. The requirement for informed consent was waived since this study involved no patient interventions such as treatments, examinations, or tests; no patients were interviewed or contacted; and all data utilized were previously recorded in our treatment registry. Additionally, no personally identifiable information, including names, identification numbers, addresses, contact details, photographs, or any other data that could trace back to individual patients, was collected.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"302"}}